Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zyvox/ Linezolid · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Zyvox® / Linezolid | DRUG | - |
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: * Hospitalized/chronic care pediatric patients (birth through 17 years) * Known infections due to vancomycin-resistant enterococcus sp...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Zyvox, also known as linezolid, is an antibiotic used to treat bacterial infections. It is studied in pediatric patients with infections caused by vancomycin-resistant Enterococcus, a specific bacterium that resists many other antibiotics. Linezolid is a small molecule anti-infective developed by Pfizer, Inc. (NYSE: PFE).
Zyvox is developed and manufactured by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the company behind the linezolid brand, and the drug sits within Pfizer's infectious disease portfolio.
Zyvox, or linezolid, has been studied in Phase 3 clinical development for bacterial infections. The Phase 3 trial in the program has completed, and no trials are currently active. Linezolid is a small molecule antibiotic in the infectious disease therapeutic area.
Zyvox has been evaluated in the Phase 3 trial NCT00035854, titled "New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)." The trial enrolled 13 participants in the United States, was randomized, and has completed.
Yes, Zyvox and linezolid refer to the same antibiotic. Zyvox is the brand name, while linezolid is the generic or international nonproprietary name. Both names describe the same small molecule developed by Pfizer, Inc. for treating bacterial infections.
Zyvox, or linezolid, is a small molecule antibiotic that targets bacterial infections, specifically infections caused by vancomycin-resistant Enterococcus. Its activity is directed at this resistant bacterium, which is the focus of its Phase 3 pediatric trial NCT00035854.